Novo advances third business leg with Ventus deal, says analyst
According to a Sydbank analyst, the recent agreement with Ventus is a sign that Novo Nordisk is betting on a newer area, chronic diseases.
by marketwire, translated by daniel pedersen
Novo Nordisk, known for making medicines for diabetes and bleeding disorders, has continued its foray into chronic diseases by striking an agreement with Ventus Therapeutics, a US-based biotech focused on using small molecules to treat challenging targets.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
